Form 4: Plus Therapeutics Director Richard J. Hawkins Reports Securities Transaction
SEC Form 4 Filing
Director Richard J. Hawkins of Plus Therapeutics reports the acquisition and disposal of common stock on September 12, 2024.
Summary
- On September 12, 2024, Richard J. Hawkins, a director of Plus Therapeutics, acquired 6,285 shares of common stock at a price of $1.3543 per share.
- Following this transaction, Hawkins disposed of 6,285 shares.
- After the reported transaction, Hawkins beneficially owns 11,188 shares of Plus Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a transaction by a company director. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider trading activity, which is common for directors and officers of publicly traded companies. It provides transparency to investors regarding the buying and selling of company stock by insiders.
Stakeholder Impact
- The transaction may be of interest to shareholders as it reflects the director's activity in the company's stock.
Key Dates
| Date | Description |
|---|---|
| 09/12/2024 | Date of the securities transaction (acquisition and disposal of shares). |
| 09/16/2024 | Date of signature for the report. |
Keywords
Form 4, Beneficial Ownership, Securities Transaction, Richard J. Hawkins, Plus Therapeutics, PSTV, Director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.